RWA Wealth Partners LLC Trims Stock Holdings in Eli Lilly and Company $LLY

Key Points

• RWA Wealth Partners LLC reduced its holdings in Eli Lilly and Company by 4.2%, owning 43,302 shares worth $35.76 million after selling 1,889 shares in Q1.
• A number of institutional investors, including Wellington Management and Absolute Gestao de Investimentos, increased their positions in Eli Lilly during the same period, demonstrating continued interest despite RWA's sell-off.
• Analysts have mixed sentiments on Eli Lilly, with several downgrades but a consensus rating of "Moderate Buy" and a target price around $950.17.

RWA Wealth Partners LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.2% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 43,302 shares of the company's stock after selling 1,889 shares during the period. RWA Wealth Partners LLC's holdings in Eli Lilly and Company were worth $35,764,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Wellington Management Group LLP raised its position in Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock valued at $10,495,261,000 after purchasing an additional 81,587 shares during the period. Absolute Gestao de Investimentos Ltda. boosted its stake in shares of Eli Lilly and Company by 18.3% during the first quarter. Absolute Gestao de Investimentos Ltda. now owns 387 shares of the company's stock worth $320,000 after buying an additional 60 shares during the period. Qtron Investments LLC lifted its position in Eli Lilly and Company by 9.2% in the first quarter. Qtron Investments LLC now owns 9,832 shares of the company's stock valued at $8,120,000 after purchasing an additional 826 shares during the period. Alpha Family Trust lifted its position in Eli Lilly and Company by 14.1% in the first quarter. Alpha Family Trust now owns 1,745 shares of the company's stock valued at $1,441,000 after purchasing an additional 215 shares during the period. Finally, Sand Hill Global Advisors LLC increased its holdings in Eli Lilly and Company by 0.5% in the first quarter. Sand Hill Global Advisors LLC now owns 8,612 shares of the company's stock valued at $7,113,000 after buying an additional 44 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Leerink Partnrs downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Guggenheim cut their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday. Finally, UBS Group decreased their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $701.51 on Monday. The stock has a market cap of $663.95 billion, a P/E ratio of 45.85, a PEG ratio of 0.98 and a beta of 0.44. The company's 50-day simple moving average is $764.55 and its 200 day simple moving average is $794.43. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $972.53. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.92 earnings per share. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.